Kornimate/medical-research-clean huggingface dataset:
coronary artery calcification assessed on pet scanner (pet : positron emission tomography)

Conditions: Coronary Artery Disease; Coronary Artery Calcification

Summary: calcification artery calcium (cac) scoring is a valuable tool for determining the risk of major adverse cardiac events. it was found that cac can be quantitatively assessed, by manual scoring or using deep-learning, on low-dose non electrocardiogram-gated, contrast-enhanced or non-enhanced computed tomography (ct-scan) performed in association of pet acquisition, with a good agreement with standard scans. the purpose of this study is to determine the impact of a systematic coronary artery calcification evaluation in patients undergoing flourine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18f-fdg pet/ct) imaging to improve primary prevention of cardiovascular diseases. a visual calcification artery calcium assessment will be made for each patient, dividing them into four groups: none, mild, moderate or heavy calcification artery calcium. when possible, a calcification artery calcium score will be computed. each patient will complete a questionnaire to collect risk factors, history of cardiovascular diseases and medications.


Eligibility criteria:
inclusion criteria: * patients referred for a 18f-fdg pt/ct imaging * patients aged 18 and older exclusion criteria: * patients who already participated in this study (in case of follow-up pet/ct scans) * unusable ct scan due to ct artifacts or poor-quality images * patients referred for a brain 18f-fdg pet/ct imaging * minors, * protected adults * pregnant or breastfeeding women

Keywords: coronary disease coronary artery calcium cardiovascular diseases 18f-fdg pet/ct (flourine-18 fluorodeoxyglucose positron emission tomography/computed tomography) enhanced ct (computed tomography)
intra-hepatic chemotherapy in patients with liver metastases from breast cancer and limited extrahepatic disease

Conditions: Metastatic Breast Cancer; Liver Metastases

Summary: this is a phase ii trial evaluating intra-hepatic chemotherapy with oxaliplatin every second week in combination with systemic capecitabine and in patients with a her2-positive tumour in combination with trastuzumab (herceptin®) in patient with non-resectable liver metastases from breast cancer. only patients with limited extrahepatic disease are included.


Eligibility criteria:
inclusion criteria:• informed consent * age \> 18 years * performance status 0-1; expected survival ≥ 3 months * patient with histologically or cytologically confirmed locally advanced or metastatic adenocarcinoma of the breast * liver metastases not suitable for local treatment * extrahepatic disease should be determined by pet-ct-scan. * no progression on treatment with capecitabine. * prior treatment with taxane (adjuvant or for metastatic disease) * metastases \< 70 % of the liver * neutrophile granulocytes \> 1.5 x 109/l og thrombocytes \> 100 x 109/l * bilirubin \< 2.0 x unl (upper normal limit). * creatinine-clearance \> 30 ml/min. * inr \< 1.6. * if the patient is her2-positive:baseline lvef ≥ 50 % exclusion criteria: * history of chemotherapy within the 4-week period prior to the start of trial medication * other current or prior malignant disease except adequately treated and cured carcinoma in situ of the cervix or squamous cell carcinoma of the skin. * previous treatment with oxaliplatin * cytotoxic or experimental treatment within a 14 days period before start of trial medication * the patient is not allowed to participate in other clinical trials. * any clinical symptoms suggesting peripheral neuropathy \< or equal to grade 2 or cns metastases (in case of clinical suspicion on cns metastases a mr or ct scan should be performed within 4 weeks before inclusion * other severe medical conditions e.g. severe cardial disease or ami \< 1 year * presence of diseases which prevent oral therapy. * patients with uncontrolled infection * pregnant or lactating women * women capable of childbearing not using a sufficient non-hormonal method of birth control * patients not able to understand the treatment or to collaborate. * prior serious or unsuspected reaction after treatment with fluoropyrimidine * known prior hypersensitivity reactions to the agents if the patient is her2-positive: * dyspnoea in due to complication related to malignant disease e.g.lung metastases with lymphangitis or other conditions with need of supportive oxygen.

Keywords: breast cancer liver metastases intrahepatic chemotherapy
evaluation of the duration of oral combination therapy in type 2 diabetes, prior to the initiation of insulin in the uk

Conditions: Diabetes Mellitus, Type 2

Summary: carry out the cost-effectiveness analysis of rosiglitazone on a population in line with the rosiglitazone license and using uk costs


Eligibility criteria:
inclusion criteria: * rosiglitazone type ii diabetes studies exclusion criteria: * studies without the required outcome
promus - registry experience at the washington hospital center, drug-eluting stent (des)

Conditions: Coronary Artery Disease

Summary: single-center registry of patients treated with at least one promus, everolimus-eluting, stent, with the primary objective to assess clinical success and safety at 30 days, 6 months and 1 year post-implantation.

interventional cardiology was revolutionized by the invention of stents, initially with the bare-metal stents (bms) and recently with the drug-eluting stents (des). the everolimus eluting stents have shown very promising results in randomized clinical trials, demonstrating a reduction of clinical and angiographic restenosis in comparison to bms, and comparable clinically-driven target lesion revascularization rates in comparison with sirolimus-eluting stents. while registry data is available from outside of the united states, it will be important to collect "real-world" data regarding the stent usage and outcomes in the united states. in this study we propose to follow patients who received at least one promus® stent for at least 1 year post initial stent implantation.

Eligibility criteria:
inclusion criteria: * patients, male or female, \>18 years of age * patients who received at least one promus drug-eluting stent at the washington hospital center exclusion criteria: * n/a
a cognitive behavioral therapy of primary obsessions in obsessive compulsive disorder

Conditions: Obsessive Compulsive Disorder

Summary: a new cognitive behavioral therapy to target distorted appraisals characteristic of primary obsessions in obsessive compulsive disorder

participants will be phone-screened to determine broad suitability and interest in being in the study, as well as availability. following telephone screening, participants will meet with a clinician who will administer a semi-structured interview to determine diagnostic status followed by a more specific standard semi-structured interview to measure symptom strength in those participants who meet diagnostic criteria of ocd (primary obsessions). participants will then be invited to join the study. participants will be randomly assigned to either immediate treatment or delayed treatment (three month delay). participants will then be again be randomly assigned to either cognitive behavior therapy (cbt) or stress management therapy (smt). the delayed participants (wait list control) will be randomly assigned to either of the two active treatment groups in three months time. both active treatment conditions involve one hours, individual treatment sessions for 12 consecutive weeks by one of the treating psychologists. all participants will also be asked to complete a package of psychometric questionnaires before treatment. participants assigned to the delayed treatment condition will be asked to complete these questionnaires again before proceeding to treatment once they have completed the three month wait. the participants will be re-evaluated at the end of treatment, at six months after treatment, and at one year after treatment, using the same assessment procedure.

Eligibility criteria:
inclusion criteria: involves: 1. a primary diagnosis of ocd, 2. an absence of overt compulsions associated with the primary obsessions, 3. functional impairment due to ocd for at least one year, 4. age range 18-65 years, 5. fluency in spoken and written english, 6. a willingness to undergo random assignment to treatment, and to complete the assigned treatment and planned assignments. exclusion criteria: 1. presence of a severe depressive disorder with suicidal intent requiring immediate intervention, 2. evidence of organic mental disorder, active thought disorder, current alcohol or drug dependence, or mental retardation, 3. concurrent psychological treatment for any axis (i) or (ii) disorder, aside from supportive therapy for depression, and 4. commencement or change in psychotropic medication in the three months prior to initial assessment through to post-treatment assessment.

Keywords: cognitive behavioral therapy primary obsessions obsessive compulsive disorder compulsive disorder
effects of lower limb fitness program in children with ds

Conditions: Down Syndrome

Summary: down syndrome is a congenital disorder resulting from the trisomy of the human chromosome 21, which will determine, among other characteristics, intellectual disability and growth retardation. reduced muscular strength, cardiovascular capacity, sleep problems, and impaired walking performance are also observed in down syndrome participants. the estimated global prevalence is around 0.1% of live births. children with down's syndrome (ds) often have greater postural sway and delay in motor development. muscle weakness and hypotonia, particularly of the lower extremities are theorized to impair their overall physical health and ability to perform daily activities. posture, balance, and movement issues are common in children with down syndrome. the purpose of this study is to examine the effects of lower limb fitness program on dynamic balance and mobility in children with down syndrome. this study explore that lower limb fitness program could improve the dynamic balance and mobility in children with ds.

group a: experimental group: group a will receive range of motion for 5 minutes involving movements that stretch and strengthen the muscles and improve the stability. proprioceptive training for 5 minutes which involve single-leg balance start with 20-30 seconds per leg and gradually increase to 1 minute 2-3 sets per leg. weight bearing exercises on an uneven surface (such as bosu ball or stability disc) and jumping rope 5-10 minutes/session. all proprioceptive training done firstly with eyes open and then with close eyes. squat-to-stand training proprioceptive training lower extremity. this intervention aims to get the muscles ready before the actual intervention and improve proprioceptive ability. exercises will be given three times a week for 6 weeks with session conducting 45 minutes per sessions which involve squat-to-stand training will repeat 30 times 3 sets for 20 min. 2minute break after 1 set.. balance training which involves standing activities with support, progressing to unsupported as tolerated for 10 minutes/session. group b: control group: in control group routine therapy will be given 3 times a week for 6 weeks with session conducting 45 minutes per sessions which involve standing balance exercises, sitting from chair to stand, heal to toe stand will be performed. data will be assessed by assessor at baseline by single leg stance test and at the end of 6th session of treatment (pre and post).

Eligibility criteria:
inclusion criteria: * age 6-12 years * both genders. * single leg stance test: if unable to stand for 5 seconds or less client at greater risk of injury from fall. * ability to understand and follow basic instructions. * deficits in balance exclusion criteria: * children who are unable to engage in a structured fitness program due to behavioral or physical limitations. * children who have undergone lower limb surgery or experienced significant lower limb injuries in the past six months

Keywords: down syndrome dynamic balance lower limb fitness program,
low-fat, high-fiber diet compared to a standard diet in treating patients with prostate cancer

Conditions: Prostate Cancer

Summary: rationale: a low-fat, high-fiber diet may slow the growth of prostate cancer. purpose: randomized phase ii trial to compare the effectiveness of a low-fat, high-fiber diet with that of a standard diet in treating patients who have prostate cancer.

objectives: * compare the inhibition of growth of human prostate cancer cell lines by serum from patients with prostate cancer before and after being fed a low fat, high fiber diet. * determine the underlying mechanism through which a low fat, high fiber diet affects the growth of prostate cancer cell lines. * determine whether a low fat, high fiber diet inhibits the growth of prostate cancer cell lines through androgen-dependent and/or androgen- independent mechanisms in these patients. * determine the growth factors, hormones, and/or binding proteins that may be responsible for affecting the growth of prostate cancer cell lines in these patients. outline: this is a randomized study. patients are randomized to 1 of 2 arms. * arm i: patients receive a low fat, high fiber diet daily for 3 weeks. * arm ii: patients receive a control diet containing the standard amounts of fat and fiber. projected accrual: a total of 40 patients (20 per arm) will be accrued for this study within 6 months.

Eligibility criteria:
disease characteristics: * diagnosis of adenocarcinoma of the prostate * previously untreated and on watchful waiting * medically able to receive dietary intervention patient characteristics: age: * 40 to 80 performance status: * not specified life expectancy: * not specified hematopoietic: * not specified hepatic: * not specified renal: * not specified other: * must be willing to travel to ucla 3 days a week for 4 weeks to obtain specially prepared foods prior concurrent therapy: biologic therapy: * not specified chemotherapy: * not specified endocrine therapy: * no concurrent luteinizing hormone-releasing hormone agonists (leuprolide or goserelin) * no concurrent androgen-receptor blocking agents (flutamide or bicalutamide) * no concurrent testosterone * no concurrent insulin * no concurrent finasteride radiotherapy: * not specified surgery: * no prior orchiectomy other: * no concurrent saw palmetto supplement

Keywords: adenocarcinoma of the prostate stage i prostate cancer stage iib prostate cancer stage iia prostate cancer stage iii prostate cancer stage iv prostate cancer
comprehensive care in type 1 diabetes and associated outcomes

Conditions: Diabetes Mellitus, Type 1

Summary: quasi-experimental, retrospective, before and after study, with a control group, to evaluate the effect of an intervention based on disease management, on metabolic control and hospitalizations, in a group of patients with type diabetes 1, attended in a provider institution of health services of the city of medellin - colombia.

evaluate the effect of an intervention based on the management of the disease, on metabolic control and the number of hospitalizations related to diabetes, in a group of patients with type 1 diabetes attended in a specialized health services provider institution in the city of medellin - colombia.

Eligibility criteria:
inclusion criteria: * patients diagnosed with type 1 diabetes. * patients affiliated to the entity administrator of health benefits plans (eps sura) * patients with age greater than or equal to 15 years, who had been referred to the institution at the discretion of the treating physician, for poor metabolic control and had to enter a hemoglobin glycated (hba1c) ≥ 7.0%. exclusion criteria: * patients who at the time of recruitment were treated with continuous insulin infusion device (insulin pump) and patients with gestational diabetes were excluded.
methodology validation: correlating adherent scalp flaking score (asfs) with phototrichogram for scalp dandruff evaluation in adult subjects

Conditions: Dandruff

Summary: this study aims to validate methods for assessing scalp hair dandruff by comparing three evaluation techniques: the adherent scalp flaking score (asfs), phototrichogram, and 60-second hair combing. these assessments will be conducted before and after hair wash interventions on adult human subjects to evaluate adherent and non-adherent scalp flakes. by comparing the results of these evaluations, the study aims to determine the consistency and reliability of each method in assessing the presence and severity of dandruff. establishing correlation between these assessment techniques is essential for validating their usefulness in evaluating the effectiveness of hair care products and treatments in reducing scalp dandruff. this research aims to improve the accuracy and reliability of dandruff evaluation methods, benefiting both dermatological research and clinical practice in managing this prevalent condition.


Eligibility criteria:
inclusion criteria: * age between 18 and 55 years (both inclusive). * good general health as determined from recent medical history. * no previous history of adverse skin conditions, and not under any medication likely to interfere with the results. exclusion criteria: * non-willing subjects and subjects with a history of allergies or specific allergic reactions upon using dermatological/cosmetic products will not be included.
preexpanded perforator flaps in children

Conditions: Contractures; Scars

Summary: contractures and broad scars of the axilla, anterior chest wall and neck have detrimental effects on functional, physical and psychological development of children. perforator flaps have already been shown to be reliable options for the reconstruction of contractures but there have been no reports demonstrating the value of preexpanded perforator flaps of dorsolateral trunk region in treatment of extensive contractures and scars of pediatric patients. the purpose of this study is to demonstrate these techniques by a case series formed of pediatric patients with broad scars and contractures of anterior chest wall, axilla, neck and breasts. seven pediatric patients (mean age, 11,6 years) who were treated by preexpanded perforator flaps are presented. by this means, clinical experience on intercostal artery perforator (icap) flap, thoracodorsal artery perforator (tdap) flap, circumflex scapular artery perforator (csap) flap and lumbar artery perforator flap was shared. flaps as large as 20,5x10,5 cm in size could be successfully transferred in pediatric patients. broad scar tissues were resurfaced with broad flaps carrying similar characteristics with the uninjured anterior chest wall and neck skin in six of our patients. in one patient with partial necrosis, full thickness skin graft was used for the residual defect. the mean duration of postoperative (after flap transfer) follow-ups was 17,2 months. the preexpanded tdap, icap and csap flaps are revealed to be useful reconstructive options for the treatment of scars and contractures of anterior chest wall, axilla, neck and breast in pediatric patients.


Eligibility criteria:
inclusion criteria: * pediatric age group * broad scars and contractures exclusion criteria: * age over 18 years * minimal scars and skin defects that could be treated by minor interventions
circulating " cancer cells / macrophage " hybrid cells in patients with sarcoma?

Conditions: Sarcoma

Summary: pilot, prospective, monocentric study aimed at evaluating the rate of patients with circulating "cancer cell/macrophage" hybrid cells in the peripheral blood. the study will be conducted on a population of patients with sarcoma and treated in the context of routine care. for each included patient, blood samples will be collected during baseline visit and after the initiation therapy. at the end of the 2nd blood collection, the patient will have completed his participation in the study.


Eligibility criteria:
inclusion criteria: 1. patient with one of the following subtypes of soft tissue or bone sarcomas: leiomyosarcoma, dedifferentiated liposarcoma, myxoid liposarcoma, synovialosarcoma, osteosarcoma, ewing's sarcoma. 2. diagnosis of sarcoma histologically confirmed by the rreps network (réseau de référence en pathologie des sarcomes et des viscères) 3. age ≥ 18 years old. 4. localized or metastatic disease or recurrent disease. 5. patient who has not yet initiated specific treatment for sarcoma. 6. patient affiliated to a social health insurance in france. 7. patient having signed informed consent prior to inclusion in the study and prior to any specific study procedures. exclusion criteria: 1. patient with any other histological subtype of sarcoma, including pleomorphic sarcoma. 2. associated pathology(s) that may prevent the proper conduct of the procedure under consideration. 3. pregnant or breastfeeding woman. 4. any psychological, family, geographical or sociological condition that prevents compliance with the medical follow-up and/or procedures of the study protocol. 5. patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).

Keywords: leiomyosarcoma dedifferentiated liposarcoma myxoid liposarcoma synovialosarcoma osteosarcoma ewing's sarcoma cancer cell/macrophage hybrid cells hybrid cells
endoscopic tympanoplasty: single versus double flap technique

Conditions: Tympanic Membrane Perforation

Summary: aim of this study is to compare results of double and single flap techniques for tympanoplasty in chronic suppurative otitis media patients. inclusion criteria include total or subtotal tympanic membrane perforations with limited anterior remnant and should be dry for at least 3 months. patients with persistent discharge, cholesteatoma, ossicular affection or those with recurrent perforations after previous myringoplasty were excluded. also, patients with uncontrolled diabetes, chronic liver and kidney diseases and immuno-compromised patients are not included in this study. patients are divided into two groups, endoscopic double flap group and endoscopic single flap group. healing and hearing outcomes were evaluated 3 months postoperative. also, post-operative pain scores and complications were assessed.


Eligibility criteria:
inclusion criteria: * patients with chronic suppurative otitis media with total or subtotal tympanic membrane perforation with limited anterior remnant. * dry perforation for at least 3 months. exclusion criteria: * recurrent perforation after previous myringoplasty. * ossicular disruption or fixation. * immune-compromised patients including uncontrolled diabetics, chronic liver and kidney diseases.
clinical pharmacogenetic study of sorafenib in egyptian patients with hepatocellular carcinoma

Conditions: HCC; Hepatocellular Carcinoma

Summary: the current study will aim to maximize the therapeutic effect and to minimize the adverse effects of sorafenib in hcc through pharmacogenomic analysis of vegfa and kdr genetic polymorphisms.


Eligibility criteria:
inclusion criteria: * age of all studied subjects ≥ 18 years old * all patients with hepatocellular carcinoma will be included in group i. * patients not treated with systemic tkis exclusion criteria: * patients presented with liver tumors other than hcc. * patients with child-pugh grade c for liver function. * patients with other malignancies. * patients with chronic inflammatory disorders. * patients with severe organ dysfunction such as heart, lung, and kidney. * patients who cannot tolerate or are allergic to sorafenib. * patients with severe coagulation dysfunction were uncorrectable. * age less than 18 years old.